Softwr

AI · head to head

LatchBio vs Qovery

LatchBio logo

LatchBio

AI

AI agents that run bioinformatics analyses, from a company that pivoted from workflow hosting

From
On request
Free plan
No
Full reviewWebsite
Qovery logo

Qovery

Cloud

Deployment platform that provisions and operates Kubernetes inside your own cloud account

From
On request
Free plan
No
Full reviewWebsite

The short version

  • Each has a real cost: LatchBio the company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.; Qovery no plan publishes a price, deployment minute overage rates are not disclosed, and there is a 14 day trial rather than a free tier, so you cannot budget or compare against alternatives without going through sales.
  • They diverge on capability: LatchBio covers Agent driven analysis, Qovery covers Bring your own cloud.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which LatchBio and Qovery actually diverge.

Attributes where LatchBio and Qovery differ
AttributeLatchBioQovery
PlatformsWebWeb, CLI, REST API, Kubernetes
CategoryAICloud

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in LatchBio

  • Agent driven analysis
  • Multi assay support
  • Published benchmarks
  • White labelled portals
  • Common file format handling
  • Managed compute

Only in Qovery

  • Bring your own cloud
  • Preview environments
  • Cluster lifecycle
  • Terraform provider
  • MCP server
  • Policy as code

What people use each for

The jobs each tool is most often brought in to do.

LatchBio

  • A small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quicklynot Qovery
  • An assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw filesnot Qovery
  • A wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facilitynot Qovery
  • A research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegatednot Qovery

Qovery

  • A regulated business that must keep application data inside its own AWS account but has nobody to build a deployment platformnot LatchBio
  • Giving twenty engineers preview environments per pull request without writing and maintaining Terraform and Helm by handnot LatchBio
  • Standardising deployment across AWS and GCP when acquisitions have left the organisation on two cloudsnot LatchBio
  • Replacing a managed platform when data residency rules put every hosted option out of reachnot LatchBio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

LatchBio

  • The company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • Agent generated analysis code has to be validated by someone who could have written it, which inverts the value proposition for the small labs that most need it and cannot check the output.
  • No pricing is published, so the cost of routine agent analysis at team scale cannot be estimated without contacting sales, and compute billed through the platform makes the bill usage dependent.
  • Regulated use is a poor fit: an agent that writes non deterministic analysis code is difficult to validate under GxP, so this is a research tool rather than something that will sit in a regulated diagnostic or submission workflow.
  • The vendor publishes its own benchmarks, which is more than most competitors do, but self reported benchmarks on selected datasets are not a substitute for testing the agent on your own data before committing.

Qovery

  • No plan publishes a price, deployment minute overage rates are not disclosed, and there is a 14 day trial rather than a free tier, so you cannot budget or compare against alternatives without going through sales.
  • The GPL-3.0 engine and console do not constitute a self-hostable product, because the control plane and API are closed and the self-hosted option is gated behind Enterprise, so the open licence gives you no exit if the company changes direction.
  • Qovery provisions managed Kubernetes into your account, which means the cloud bill sits on top of the licence and Qovery initiates control plane and ingress controller upgrades on infrastructure your team is accountable for.
  • The company repositioned to agentic infrastructure in June 2026 and now ships a deployment platform, a browser development portal and autonomous coding agents concurrently, so a buyer of the deployment product is not at the centre of the roadmap.
  • Team and Business are capped at two and three connected clusters with fixed 4 vCPU CI runners and no single sign-on on Team, which pushes teams of moderate size onto quoted Enterprise pricing earlier than the plan names imply.

Pricing, plan by plan

LatchBio

On request
  • LatchBio Platform$undefined/year
    • Quoted through a sales process
    • Interactive sandbox available for trying the agent before contracting
    • Enterprise and white labelled portal deployments priced separately

Qovery

On request
  • Team$undefined/year
    • Billed on usage with no published rate card
    • 10 users, up to 100 environments, 2 connected clusters
    • 5,000 deployment minutes and 7 day audit logs
  • Business$undefined/year
    • Billed on usage with no published rate card
    • 20 users, up to 250 environments, 3 connected clusters
    • 10,000 deployment minutes and 30 day audit logs
  • Enterprise$undefined/year
    • Custom users, environments and clusters
    • Self-hosted or air-gapped control plane
    • On-premises and bring-your-own-Kubernetes

Which should you pick?

Choose LatchBio if

  • You need agent driven analysis.
  • You also want multi assay support.
LatchBio review

Choose Qovery if

  • You need bring your own cloud.
  • You work on Web, CLI, REST API, Kubernetes.
  • You also want preview environments.
Qovery review

Questions people ask

Is LatchBio or Qovery better?
Neither clearly leads. LatchBio starts at On request and Qovery at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, LatchBio or Qovery?
LatchBio starts at On request and Qovery at On request.
Does LatchBio or Qovery run on more platforms?
LatchBio runs on Web. Qovery runs on Web, CLI, REST API, Kubernetes.
What is LatchBio best used for?
LatchBio is most often used for a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly, an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files, a wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facility, a research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegated. Of those, a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly and an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files are not what Qovery is typically brought in for.
What can LatchBio do that Qovery cannot?
LatchBio covers Agent driven analysis, Multi assay support, Published benchmarks, White labelled portals. Qovery covers Bring your own cloud, Preview environments, Cluster lifecycle, Terraform provider.

Answered from the vendors’ own pages

LatchBio: Is LatchBio still selling the original workflow platform?

The company is now led by agent.bio and its agent products. Buyers evaluating the older Python SDK workflow platform should confirm current support directly.

Qovery: Does Qovery run my applications on its own servers?

No. It provisions and operates Kubernetes inside your AWS, GCP, Azure or Scaleway account, so compute and data stay with your cloud provider and that bill is entirely separate from the Qovery licence.

LatchBio: Can I try it before buying?

Yes. There is an interactive sandbox where you can upload data and run the agent before entering a sales conversation.

Qovery: Can I self-host Qovery?

Only on Enterprise. The deployment engine and console are GPL-3.0, but the control plane is closed source and the self-hosted and air-gapped deployments are commercial Enterprise features.

LatchBio: Is it suitable for regulated work?

Not really. Non deterministic agent generated code is hard to validate under GxP, so treat it as a research and exploration tool.

Qovery: What does it cost?

Qovery does not publish a rate card. Team and Business are billed on usage and quoted through sales, and Enterprise is fully custom. There is a 14 day trial with no card required.

LatchBio: What data types does it handle?

Single cell RNA sequencing, spatial transcriptomics, epigenomics, proteomics and pharmacology data, ingesting FastQ, H5AD and spreadsheet formats.

Qovery: What survives if I stop paying?

The Kubernetes cluster and the workloads keep running in your cloud account, but you lose the console, the deployment pipeline, preview environments and every process built on top of them.

Share

Related pages

More on LatchBio

More on Qovery

Keep looking

Other head to heads